Zimbuck – Your Market. Your Community.
🚨 BREAKING: FDA REJECTS SUMMIT (SMMT) LUNG CANCER DRUG

The FDA issued a Complete Response Letter for Summit Therapeutics' ivonescimab plus chemotherapy in previously treated EGFR-mutated lung cancer. The HARMONi trial delayed progression but showed no statistically significant survival benefit — the benefit regulators required.

Summit shares were indicated 20% lower overnight after closing at $14.15 on Friday. Partner Akeso plunged as much as 32% in Hong Kong.

This is news, not financial advice.

📺 Full videos daily on YouTube — subscribe: https://www.youtube.com/@Zimbuckapp
Join the conversation on Zimbuck — the finance social platform for traders & investors: https://zimbuck.com

#SMMT #SummitTherapeutics #FDA #Biotech #Stocks #StockMarket #LungCancer #Investing
Love
Like
6
56 Weergaven